{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:56:45Z","timestamp":1791356205587,"version":"4.3.1"},"reference-count":0,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[1991,7,1]],"date-time":"1991-07-01T00:00:00Z","timestamp":678326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The FASEB Journal"],"published-print":{"date-parts":[[1991,7]]},"abstract":"<jats:p>\n                    The immunodeficiency virus type 1 is a complex retrovirus. In addition to genes that specify the proteins of the virus particle and the replicative enzymes common to all retroviruses, HIV\u20101 specifies at least six additional proteins that regulate the virus life cycle. Two of these regulatory genes,\n                    <jats:italic>tat<\/jats:italic>\n                    and rev, specify proteins essential for replication. These proteins bind to specific sequences of newly synthesized virus RNA and profoundly affect virus protein expression. Tat and rev appear to be prototypes of novel eukaryotic regulatory proteins. These two genes may play a central role in regulating the rate of virus replication. Three other viral genes,\n                    <jats:italic>vif, vpu<\/jats:italic>\n                    , and\n                    <jats:italic>vpr<\/jats:italic>\n                    , affect the assembly and replication capacity of newly made virus particles. These genes may play a critical role in spread of the virus from tissue to tissue and from person to person. Our understanding of the contribution of each of the virus structural proteins and regulatory genes to the complex life cycle of the virus in natural infections is incomplete. However, enough insight has been gained into the structure and function of each of these components to provide a firm basis for rational antiviral drug development.\u2014Haseltine, W. A. Molecular biology of the human immunodeficiency virus type 1.\n                    <jats:italic>FASEB J.<\/jats:italic>\n                    5: 2349\u20132360; 1991.\n                  <\/jats:p>","DOI":"10.1096\/fasebj.5.10.1829694","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T05:12:26Z","timestamp":1516857146000},"page":"2349-2360","source":"Crossref","is-referenced-by-count":127,"title":["Molecular biology of the human immunodeficiency virus type 1"],"prefix":"10.1096","volume":"5","author":[{"given":"William A.","family":"Haseltine","sequence":"first","affiliation":[{"name":"Dana\u2010Farber Cancer Institute Harvard Medical School Boston Massachusetts 02115 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[1991,7]]},"container-title":["The FASEB Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fasebj.5.10.1829694","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fasebj.5.10.1829694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T16:50:38Z","timestamp":1761670238000},"score":1,"resource":{"primary":{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/10.1096\/fasebj.5.10.1829694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,7]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1991,7]]}},"alternative-id":["10.1096\/fasebj.5.10.1829694"],"URL":"https:\/\/doi.org\/10.1096\/fasebj.5.10.1829694","archive":["Portico"],"relation":{},"ISSN":["0892-6638","1530-6860"],"issn-type":[{"value":"0892-6638","type":"print"},{"value":"1530-6860","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,7]]}}}